Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment

The factors contributing to the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.4 and BA.5 subvariants in populations that experienced recent surges of BA.2 and BA.2.12.1 infections are not understood. Neutralizing antibodies (NAbs) are likely to protect against se...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlin, Aaron F, Clark, Alex E, Garretson, Aaron F, Bray, William, Porrachia, Magali, Santos, AsherLev T, Rana, Tariq M, Chaillon, Antoine, Smith, Davey M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122487/
https://www.ncbi.nlm.nih.gov/pubmed/37096144
http://dx.doi.org/10.1093/ofid/ofad154
_version_ 1785029501842882560
author Carlin, Aaron F
Clark, Alex E
Garretson, Aaron F
Bray, William
Porrachia, Magali
Santos, AsherLev T
Rana, Tariq M
Chaillon, Antoine
Smith, Davey M
author_facet Carlin, Aaron F
Clark, Alex E
Garretson, Aaron F
Bray, William
Porrachia, Magali
Santos, AsherLev T
Rana, Tariq M
Chaillon, Antoine
Smith, Davey M
author_sort Carlin, Aaron F
collection PubMed
description The factors contributing to the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.4 and BA.5 subvariants in populations that experienced recent surges of BA.2 and BA.2.12.1 infections are not understood. Neutralizing antibodies (NAbs) are likely to protect against severe disease if present in sufficient quantity. We found that after BA.2 or BA.2.12.1 infection, NAb responses were largely cross-neutralizing but were much less effective against BA.5. In addition, individuals who were infected and treated early with nirmatrelvir/ritonavir (Paxlovid) had lower NAb levels than untreated individuals.
format Online
Article
Text
id pubmed-10122487
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101224872023-04-23 Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment Carlin, Aaron F Clark, Alex E Garretson, Aaron F Bray, William Porrachia, Magali Santos, AsherLev T Rana, Tariq M Chaillon, Antoine Smith, Davey M Open Forum Infect Dis Brief Report The factors contributing to the rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.4 and BA.5 subvariants in populations that experienced recent surges of BA.2 and BA.2.12.1 infections are not understood. Neutralizing antibodies (NAbs) are likely to protect against severe disease if present in sufficient quantity. We found that after BA.2 or BA.2.12.1 infection, NAb responses were largely cross-neutralizing but were much less effective against BA.5. In addition, individuals who were infected and treated early with nirmatrelvir/ritonavir (Paxlovid) had lower NAb levels than untreated individuals. Oxford University Press 2023-03-21 /pmc/articles/PMC10122487/ /pubmed/37096144 http://dx.doi.org/10.1093/ofid/ofad154 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Carlin, Aaron F
Clark, Alex E
Garretson, Aaron F
Bray, William
Porrachia, Magali
Santos, AsherLev T
Rana, Tariq M
Chaillon, Antoine
Smith, Davey M
Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
title Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
title_full Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
title_fullStr Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
title_full_unstemmed Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
title_short Neutralizing Antibody Responses After Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 and BA.2.12.1 Infection Do Not Neutralize BA.4 and BA.5 and Can Be Blunted by Nirmatrelvir/Ritonavir Treatment
title_sort neutralizing antibody responses after severe acute respiratory syndrome coronavirus 2 ba.2 and ba.2.12.1 infection do not neutralize ba.4 and ba.5 and can be blunted by nirmatrelvir/ritonavir treatment
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122487/
https://www.ncbi.nlm.nih.gov/pubmed/37096144
http://dx.doi.org/10.1093/ofid/ofad154
work_keys_str_mv AT carlinaaronf neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT clarkalexe neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT garretsonaaronf neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT braywilliam neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT porrachiamagali neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT santosasherlevt neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT ranatariqm neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT chaillonantoine neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment
AT smithdaveym neutralizingantibodyresponsesaftersevereacuterespiratorysyndromecoronavirus2ba2andba2121infectiondonotneutralizeba4andba5andcanbebluntedbynirmatrelvirritonavirtreatment

Ejemplares similares